LETTER
NIH Study of Rheumatoid Arthritis
Dimitrios T. Boumpas, MD
1 September 1994 | Volume 121 Issue 5 | Page 389
TO THE EDITOR:
Patients with rheumatoid arthritis who have failed to respond to treatment with prednisone and another second-line agent (such as methotrexate, azathioprine, intramuscular gold, penicillamine, cyclosporine, or alkylating agents) are being sought for a therapeutic study involving an innovative immunosuppressive regimen with fludarabine. Inquires may be directed to Dimitrios T. Boumpas, MD, (301-496-3092) or Barri J. Fessler, MD, (301-496-3092), National Institutes of Health, Building 10, Room 3N-112, Bethesda, Maryland 20892.
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Article
